Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI fat analysis may reveal breast cancer before tumors grow

NCT ID NCT03949946

Diagnosis Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers are testing whether a special MRI technique that maps fat composition in breast tissue can improve early detection of breast cancer. The study compares women with a BRCA1/2 or TP53 gene mutation, who are at high risk, with women who already have invasive ductal carcinoma. By measuring saturated, monounsaturated, and polyunsaturated fatty acids in the breast, the team hopes to find a difference that could signal cancer early. The MRI is non-invasive and uses no harmful radiation, making it a potential screening tool for high-risk populations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetic resonance imaging (MRI) with contrast agent
What this could lead to
If it works, this could lead to a more accurate, radiation-free screening tool for women at high genetic risk of breast cancer, potentially catching tumors earlier.
What could go wrong
This is a small early-stage study with only 40 participants, so results may not apply broadly. The technique is experimental and needs validation before it could be used in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jun 2019

Finished

Nov 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female participants confirmed to be BRCA1/2 and TP53 gene carriers and females participants confirmed to have invasive ductal carcinoma of the breast.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female over 18 years old * BRCA1/2 or TP53 gene carriers (high-risk group) * invasive ductal carcinoma of the breast (patient group) * not having any metabolic disorders (e.g., diabetes) * not on any long term medications that may affect lipid metabolism (e.g., statins) Exclusion Criteria: * female under 18 years old * male * affected by metabolic disorders (e.g., diabetes) * on long term medications that affect lipid metabolism (e.g., statins) * contraindicated for MR investigations (poor renal function and metal implants) * concurrent cancer in other sites * concurrent hormone treatment, chemotherapy or underwent surgery * non-English speakers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive ductal breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Aberdeen Biomedical Imaging Centre

    Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.